言語を選択

LIF R

LIF R 詳細

英語名	Leukemia inhibitory factor receptor	市販薬剤の数	0
治験薬の数	2	ターゲットの別称	LIF receptor，LIF-R，CD118
研究＆開発段階	Phase 2 Clinical

英語名	Leukemia inhibitory factor receptor
ターゲットの別称	LIF receptor，LIF-R，CD118
市販薬剤の数	0
治験薬の数	2
研究＆開発段階	Phase 2 Clinical

LIF R 製品リスト

属性
Protein (1)
製品ライブラリ
オンライン (1)
種
Human (1)
タグ
Fc Tag (1)
マーカー
Unconjugated (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
LIR-H4252	Human	HEK293	Human LIF R / CD118 Protein, Fc Tag

総数量1

LIF Rバックグランド

Leukemia inhibitory factor receptor is also known as LIFR; CD118; FLJ98106; FLJ99923; LIF-R; SJS2; STWS; SWS, is the receptor for leukemia inhibitory factor (LIF). The leukemia inhibitory factor is a polyfunctional cytokine that affects the differentiation, survival, and proliferation of a wide variety of cells in the adult and the embryo. LIF action appears to be mediated through a high-affinity receptor complex composed of a low-affinity LIF binding chain (LIF receptor) and a high-affinity converter subunit, gp130. Both LIFR and gp130 are members of a family of cytokine receptors that includes components of the receptors for the majority of hematopoietic cytokines and for cytokines that affect other systems, including the ciliary neurotrophic factor, growth hormone and prolactin Defects in LIFR are the cause of Stueve-Wiedemann syndrome (SWS), a severe autosomal recessive condition and belongs to the group of the bent-bone dysplasias.

LIF R分子の別称

LIFR,CD118,FLJ98106,FLJ99923,SJS2,STWS,SWS

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Cardiotrophin-1 (Digna Biotech/Biotecnol)	CT-1	Phase 2 Clinical	Biotecnol Sa, Digna Biotech Sl, Genentech Inc	Acute Kidney Injury; Ischemia; Liver Failure; Myocardial Reperfusion Injury	詳細
MSC-1 (Northern Biologics)		Phase 1 Clinical	Mosaic Biosciences	Carcinoma, Non-Small-Cell Lung; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours	詳細